Haibo Lei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Haibo Lei has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Chunjiang Wang
Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China
3 shared publications - Jiang Zeng
Department of Pharmacy, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China
2 shared publications - Xiang Liu
Department of Clinical Pharmacy, Xiangtan Central Hospital, The Affiliated Hospital of Hunan University, Xiangtan, China
2 shared publications - Zuojun Li
Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China
2 shared publications - Jia Chen
Clinical Pharmacy Department, Xiangtan Central Hospital (The Affiliated Hospital of Hunan University), Xiangtan, PR China
1 shared publication - Qichang Xing
Department of Clinical Pharmacy, The Central Hospital of Xiangtan (The affiliated hospital of Hunan University), Xiangtan, Hunan, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 13 January 2024
- Published by Wiley in Dermatologic Therapy
- Vol. 2024 (1)
Clinical Characteristics, Treatment, and Prognosis of Amoxicillin‐Induced AGEP/ALEP
Background. Amoxicillin was associated with acute generalized exanthematous pustulosis (AGEP), and the clinical characteristics were not clear. The purpose of this study was to explore the clinical characteristics of amoxicillin‐induced AGEP and to provide a basis for prevention and treatment. Methods. Case reports and case series of amoxicillin‐induced AGEP were collected for retrospective analysis by searching the Chinese and English databases from inception to January 31, 2023. Results. A total of 46 patients were included with a median age of 40 years (range 1.4, 87). The onset time of AGEP ranged from 6 hours to 28 days, with a median of 2.5 days. Fever occurred in 32 patients (69.6%), and pruritus occurred in 13 patients (28.3%). Ten patients (21.7%) had mucous membrane involvement and systemic involvement, respectively. Twenty‐two patients had elevated neutrophils, with a median of 12850/mm3 (range 7880, 29140). Skin biopsy mainly showed subcorneal pustules (22 cases, 47.8%), spongy pustules (14 cases, 30.4%), and inflammatory cell infiltration (26 cases, 56.5%). Skin lesions disappeared in a median of 10 days (range 2, 42) after discontinuation of amoxicillin and administration of topical steroids (26 cases, 56.5%) as well as systemic corticosteroids (13 cases, 28.3%). Conclusions. AGEP is a rare complication of amoxicillin and is self‐limiting. Clinicians should correctly identify AGEP and should avoid represcribing amoxicillin. Clinicians should correctly identify AGEP and avoid represcribing amoxicillin, which can prevent unnecessary treatment measures.
- 13 January 2024
- Published by Wiley in Dermatologic Therapy
- Vol. 2024 (1)
Open AccessClinical Characteristics, Treatment, and Prognosis of Amoxicillin‐Induced AGEP/ALEP
Background. Amoxicillin was associated with acute generalized exanthematous pustulosis (AGEP), and the clinical characteristics were not clear. The purpose of this study was to explore the clinical characteristics of amoxicillin‐induced AGEP and to provide a basis for prevention and treatment. Methods. Case reports and case series of amoxicillin‐induced AGEP were collected for retrospective analysis by searching the Chinese and English databases from inception to January 31, 2023. Results. A total of 46 patients were included with a median age of 40 years (range 1.4, 87). The onset time of AGEP ranged from 6 hours to 28 days, with a median of 2.5 days. Fever occurred in 32 patients (69.6%), and pruritus occurred in 13 patients (28.3%). Ten patients (21.7%) had mucous membrane involvement and systemic involvement, respectively. Twenty‐two patients had elevated neutrophils, with a median of 12850/mm3 (range 7880, 29140). Skin biopsy mainly showed subcorneal pustules (22 cases, 47.8%), spongy pustules (14 cases, 30.4%), and inflammatory cell infiltration (26 cases, 56.5%). Skin lesions disappeared in a median of 10 days (range 2, 42) after discontinuation of amoxicillin and administration of topical steroids (26 cases, 56.5%) as well as systemic corticosteroids (13 cases, 28.3%). Conclusions. AGEP is a rare complication of amoxicillin and is self‐limiting. Clinicians should correctly identify AGEP and should avoid represcribing amoxicillin. Clinicians should correctly identify AGEP and avoid represcribing amoxicillin, which can prevent unnecessary treatment measures.
- Open Access
- 5 April 2022
- Published by S. Karger AG in Pharmacology
- Vol. 107 (7-8) , 351-358
Analysis of the Clinical Characteristics of Hyponatremia Induced by Trimethoprim/Sulfamethoxazole
Background: Trimethoprim-sulfamethoxazole (TMP/SMX) causes hyperkalemia, and hyponatremia caused by TMP/SMX is a challenge for clinicians. We described the clinical features of hyponatremia induced by TMP/SMX after collecting cases. Summary: The median age of the 24 patients (10 males and 14 females) was 67 years (range: 28–90 years). Hyponatremia induced by TMP/SMX manifested as nausea (41.7%) and vomiting (29.2%) or asymptomatic hyponatremia (20.8%). The median duration of hyponatremia was 5 days (range: 3–10 days). The median serum sodium concentration was 118 mmol/L (range: 101–128.1 mmol/L). The serum sodium levels gradually returned to the normal range at 4 days (median; range: 2–14 days) after withdrawing TMP/SMX. Key Messages: TMP/SMX-induced hyponatremia is a rare and serious adverse reaction. Clinicians should be aware of electrolyte disturbances caused by TMP/SMX and should always consider electrolyte monitoring.
- 5 April 2022
- Published by S. Karger AG in Pharmacology
- Vol. 107 (7-8) , 351-358
Open AccessAnalysis of the Clinical Characteristics of Hyponatremia Induced by Trimethoprim/Sulfamethoxazole
Background: Trimethoprim-sulfamethoxazole (TMP/SMX) causes hyperkalemia, and hyponatremia caused by TMP/SMX is a challenge for clinicians. We described the clinical features of hyponatremia induced by TMP/SMX after collecting cases. Summary: The median age of the 24 patients (10 males and 14 females) was 67 years (range: 28–90 years). Hyponatremia induced by TMP/SMX manifested as nausea (41.7%) and vomiting (29.2%) or asymptomatic hyponatremia (20.8%). The median duration of hyponatremia was 5 days (range: 3–10 days). The median serum sodium concentration was 118 mmol/L (range: 101–128.1 mmol/L). The serum sodium levels gradually returned to the normal range at 4 days (median; range: 2–14 days) after withdrawing TMP/SMX. Key Messages: TMP/SMX-induced hyponatremia is a rare and serious adverse reaction. Clinicians should be aware of electrolyte disturbances caused by TMP/SMX and should always consider electrolyte monitoring.
- 27 March 2022
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 47 (8) , 1218-1224
Analysis of clinical features of tacrolimus‐induced optic neuropathy
Tacrolimus is associated with optic neuropathy. The clinical features of tacrolimus-induced optic neuropathy (TION) are unclear. The purpose of this article is to explore the clinical features of TION. TION-related case reports were collected and analysed by searching Chinese and English databases from 1989 to 31 December 2021. Twelve males and 7 females were included, with a median age of 54 years (range 23-66). TION onset time ranged from 2 months to 16 years after administration, and the main clinical features were blurred vision (4 cases), decreased visual acuity (7 cases), decreased visual acuity (5 cases), grey films (3 cases), visual field damage (3 cases) and headache (2 cases). Fifteen patients developed bilateral optic neuropathy. Ophthalmological examination showed visual acuity ranging from 20/25 to blindness, pupillary examination revealed relative afferent pupillary defect in 9 patients and marked decrease in colour vision in 15 eyes. The optic disc showed pallor (10 cases), oedema (8 cases), atrophy (4 cases) and haemorrhage (2 cases). After discontinuation or dose reduction of tacrolimus, symptoms improved in 10 patients, 1 patient recovered completely, and 4 patients did not recover. TION presents diverse clinical manifestations. TION should be promptly identified and treated to prevent severe and permanent vision loss.
- 27 March 2022
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 47 (8) , 1218-1224
Analysis of clinical features of tacrolimus‐induced optic neuropathy
Tacrolimus is associated with optic neuropathy. The clinical features of tacrolimus-induced optic neuropathy (TION) are unclear. The purpose of this article is to explore the clinical features of TION. TION-related case reports were collected and analysed by searching Chinese and English databases from 1989 to 31 December 2021. Twelve males and 7 females were included, with a median age of 54 years (range 23-66). TION onset time ranged from 2 months to 16 years after administration, and the main clinical features were blurred vision (4 cases), decreased visual acuity (7 cases), decreased visual acuity (5 cases), grey films (3 cases), visual field damage (3 cases) and headache (2 cases). Fifteen patients developed bilateral optic neuropathy. Ophthalmological examination showed visual acuity ranging from 20/25 to blindness, pupillary examination revealed relative afferent pupillary defect in 9 patients and marked decrease in colour vision in 15 eyes. The optic disc showed pallor (10 cases), oedema (8 cases), atrophy (4 cases) and haemorrhage (2 cases). After discontinuation or dose reduction of tacrolimus, symptoms improved in 10 patients, 1 patient recovered completely, and 4 patients did not recover. TION presents diverse clinical manifestations. TION should be promptly identified and treated to prevent severe and permanent vision loss.